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The aim of our work here was to evaluate the immunogenicity of 60 mycobacterial
antigens, some of which have not been previously assessed, notably a novel series
of in vivo-expressed Mycobacterium tuberculosis (IVE-TB) antigens. We enrolled 505
subjects and separated them in individuals with and without latent tuberculosis
infection (LTBI) vs. patients with active tuberculosis (TB). Following an overnight and
7 days stimulation of whole blood with purified recombinant M. tuberculosis antigens,
interferon-γ (IFN-γ) levels were determined by ELISA. Several antigens could statistically
significantly differentiate the groups of individuals. We obtained promising antigens from
all studied antigen groups [dormancy survival regulon (DosR regulon) encoded antigens;
resuscitation-promoting factors (Rpf) antigens; IVE-TB antigens; reactivation associated
antigens]. Rv1733, which is a probable conserved transmembrane protein encoded in
DosR regulon, turned out to be very immunogenic and able to discriminate between the
three defined TB status, thus considered a candidate biomarker. Rv2389 and Rv2435n,
belonging to Rpf family and IVE-TB group of antigens, respectively, also stood out as LTBI
biomarkers. Although more studies are needed to support our findings, the combined use
of these antigens would be an interesting approach to TB immunodiagnosis candidates.
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INTRODUCTION
Tuberculosis (TB) remains one of the most death-causing
microorganism worldwide (World Health Organization, 2013).
The increasing numbers of drug-resistant TB cases evidence that
there is an urgent need for effective diagnosis, drugs and vaccines
(Mwaba et al., 2011; Abubakar et al., 2013). The control of latent
TB, a stage in which a person is infected with Mycobacterium
tuberculosis (Mtb) but does not currently have active disease,
plays an important role for disease control, since dormant bacilli
are an enormous reservoir of potential TB cases (Rustad et al.,
2009).
M.tb can live in a latent stage without causing any clin-
ical symptom and has a potential of reactivation during all
the infected individual lifetime. In fact, about one third of the
world population is considered to be latently infected (Corbett
et al., 2003). The diagnosis of latent tuberculosis infection (LTBI)
through the classic tuberculin skin test (TST) has a lack of speci-
ficity, and its sensitivity is low in high-risk groups of progression
to active TB. The new interferon (IFN)-γ release assays (IGRAs)
are immunodiagnostic methods based on the in vitro quan-
tification of the cellular immune response. The detection of
IFN-γ released by sensitized T cells stimulated with specific
M.tb antigens enables the identification of infected individu-
als. The main antigens used in IGRAs, the 6-kDa M.tb early-
secreted antigenic target (ESAT)-6 protein, 10-kDa culture fil-
trate protein (CFP-10), coded in the region of difference (RD)
1, and TB7.7, coded in RD11, are present in M.tb but not in
any Mycobacterium bovis bacillus Calmette-Guérin (BCG) vac-
cine strain nor in the majority of non-tuberculous mycobacteria
(Andersen et al., 2000). Although their specificity is better than
in TST, IGRAs do not discriminate between active disease and
LTBI (Latorre et al., 2009) and do not clearly distinguish between
a recently acquired infection and remote LTBI (Esmail et al.,
2012; Pollock et al., 2013). Moreover, their sensitivity barely
exceed 80%, and the response level against the antigens used
does not seem to indicate high risk of progression to active TB.
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There is a need of new TB antigens as biomarkers for LTBI
immunodiagnosis.
During LTBI, M.tb is contained within granulomas, which
are formed by activated macrophages and other host compo-
nents that isolate the infected cells in an organized structure and
create an environment that suppresses M.tb replication (Esmail
et al., 2012). Bacilli must adapt to a variety of environment
stresses including reduced oxygen tension, iron limitation, nutri-
ent deprivation, low pH and production of host factors such as
nitric oxide and carbon monoxide. Some in vitromodels demon-
strated thatM.tb is capable of an extensive repertoire of metabolic
realignments to enter a defined non-replicating state. The initial
response of M.tb is encoded by the dormancy survival regulon
(DosR, also called DevR, Rv3133c), which leads to induction of
a set of ∼50 genes, many of unknown function. DosR controls
the expression of genes that allow the bacteria to use alterna-
tive energy sources, especially lipids, and genes encoding factors
that are selectively recognized by T cells from humans with LTBI
(Ernst, 2012). This initial response is followed by a more extensi-
ble and more stable response called Enduring Hypoxic Response
(EHR), which is comprised of 230 genes involved in the control of
the regulatory factors and enzymatic machines of the long-term
bacteriostasis program of non-replicating M.tb (Rustad et al.,
2008). The antigens expressed byM.tb vary during the continued
pressure mounted by host immune response in the course of the
infection (Honer zu Bentrup and Russell, 2001; Demissie et al.,
2006). Using in vitromodels which mimic the conditions that the
tubercle bacillus encounter within the host as infection progresses
from latency to active disease, some infection phase-dependent
genes have been identified and believed to be candidates for
immunodiagnostics or for future vaccines (Mukamolova et al.,
1998; Zvi et al., 2008; Ottenhoff and Kaufmann, 2012).
DosR regulon is crucial for rapid resumption of growth by
involving resuscitation-promoting factors (Rpf) once M.tb exits
the hypoxic non-respiring state. M.tb contains five Rpf -like pro-
teins that are implicated in resuscitation of this microorganism
from dormancy to reactivation via amechanism involving hydrol-
ysis of the peptidoglycan by Rpfs and partnering proteins (Ernst,
2012).
The in vitromodels mentioned above supposed to recapitulate
relevant environmental stress conditions that M.tb encounters
upon host infection, which allow to identify differentially regu-
lated M.tb genes. However, they present some limitations: many
of these environmental stress factors may not be well known yet;
theremay be additive or synergistic effects betweenmultiple stress
factors in vivo that may easily be missed when studied in isolation
in vitro; and certain key features of host response-induced stress
cannot readily be recapitulated in vitro, including granuloma
formation and TB necrosis (Commandeur et al., 2013).
For these reasons, different approaches have been developed
to analyze the gene expression profiles of intracellular M.tb using
infected human or murine macrophages, infected murine tis-
sue or artificial granuloma mouse models (Schnappinger et al.,
2003; Karakousis et al., 2004; Talaat et al., 2004; Cappelli
et al., 2006). Specifically, several M.tb genes have been found
to be differentially expressed in the lungs of mice strains with
high susceptibility to TB during in vivo infection, the so-called
in vivo-expressed M.tb (IVE-TB) genes. Interestingly, some of
these IVE-TB genes had been also described as induced for nutri-
ent deprivation in in vitromodels (Commandeur et al., 2013).
Some M.tb infection phase-dependent antigens have already
been tested in whole-blood assays or in peripheral blood
mononuclear cells and may be differentially recognized in indi-
viduals with different TB status, that is, subjects with no risk of
M.tb infection, LTBI individuals and active TB patients (Leyten
et al., 2006; Lin et al., 2007, 2009; Black et al., 2009; Schuck
et al., 2009; Goletti et al., 2010; Commandeur et al., 2013). The
response is commonly measured through the release of IFN-γ.
Additionally, IFN-γ plays a central role in the protection against
M.tb (Cooper et al., 1993; Flynn et al., 1993; Kaufmann, 2001).
However the studies conducted in vivo, mice models of latency,
seem to merely recapitulate primary disease and are closer to
human HIV-TB co-infection. The infectious forms of TB arise
after an adequate immune response, which itself may contribute
to tissue destruction and cavitation. Hence, there has been a move
away from considering IFN-γ as protective, except in the first
encounter with the tubercle bacillus, with a renewed emphasis
on polyfunctional T cells to contain TB infection (Ernst, 2012;
Kaufmann, 2012). However, the ease of measuring IFN-γ gives it
applicability to diagnostic tests.
The study of the immune response to the potential immuno-
genic M.tb antigens described above will enlarge our knowledge
and will get us closer to the validation of a diagnostic LTBI can-
didate antigen. We hypothetized that these antigens expressed in
latency conditions and involved in reactivation of the dormant
bacterial will mainly induce IFN-γ response in LTBI infected
patients, and not in no LTBI individuals.
This prospective study aims to evaluate the whole blood IFN-γ
response to 60 M.tb recombinant antigens, the immunogenicity
of some of them has not yet been assessed: 6 DosR regulon-
encoded antigens, 12 TB reactivation-associated antigens, 1 Rpf
antigen, 1 starvation antigen, 6 other stress response-associated
TB antigens and 34 IVE-TB antigens (2 of those were EHR and
3 were EHR/starvation), in order to identify potential candidates
for new LTBI diagnostic methods.We enrolled subjects with LTBI,
active TB patients and controls notM.tb infected.
MATERIALS AND METHODS
STUDY POPULATION
We prospectively recruited 578 patients from contact-tracing
studies, LTBI screening (such as immigrants from endemic
areas or health-care workers) and active TB patients between
October 2010 and May 2013. A detailed questionnaire from
each subject was collected, including age, birth country, pre-
vious TST, BCG vaccination status, history of prior active TB,
chest radiography, and other medical conditions (Table 1). A
total of 8mL of whole blood was collected in a heparinized
tube from each participant. The study obtained approval of the
Hospital Universitari Germans Trias i Pujol Ethics Committees
(Ref. 10/00214-28/03/2010). They supervised that all the exper-
iments were performed according to the regulatory standards.
All the study participants gave written informed consent before
entering the study.
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Table 1 | Demographic characteristics and clinical details for
individuals in this study.
No TB infected LTBI Active TB
individuals infected patients
(n = 97) (n = 306) (n = 102)
GENDER
Male 61 (62.9) 131 (42.8) 73 (71.6)
Female 36 (37.1) 175 (57.2) 29 (28.4)
ORIGIN
Spain 31 (32) 171 (55.9) 43 (42.2)
Africa 2 (2.1) 15 (4.9) 15 (14.7)
America 16 (16.5) 40 (13.1) 13 (12.7)
South-East Asia 15 (15.5) 16 (5.2) 5 (4.9)
Europe 2 (2.1) 11 (3.6) 0 (0)
Eastern Mediterranean 21 (21.6) 41 (13.4) 23 (22.5)
Western pacific 10 (10.3) 12 (3.9) 3 (2.9)
BCG VACCINATION
Yes 71 (73.2) 138 (45.1) 36 (35.3)
No 25 (25.8) 167 (54.6) 57 (55.9)
Unknown 1 (1.0) 1 (0.3) 9 (8.8)
QFN RESULT
Positive 0 (0) 182 (59.5) 21 (20.6)
Negative 97 (100) 123 (40.2) 5 (4.9)
Indeterminate 0 (0) 0 (0) 0 (0)
Not done 0 (0) 1 (0.3) 76 (74.5)
PREVIOUS TB
Yes 0 (0) 1 (0.3) 11 (10.8)
No 96 (99) 238 (77.8) 91 (89.2)
Unknown 1 (1.0) 67 (21.9) 0 (0)
IMMUNOSUPPRESSION
No 94 (96.9) 300 (98) 94 (92.2)
HIV+ 1 (1.0) 2 (0.7) 2 (2.0)
Other 2 (2.1) 4 (1.3) 6 (5.9)
TB CLINICAL FORM
Pulmonar 0 (0) 0 (0) 84 (82.4)
Ganglionar 0 (0) 0 (0) 7 (6.9)
Pleural 0 (0) 0 (0) 1 (1.1)
Pulmonar and ganglionar 0 (0) 0 (0) 2 (2.0)
Pulmonar and pleural 0 (0) 0 (0) 2 (2.0)
Disseminated 0 (0) 0 (0) 5 (4.9)
Erythema nodosum 0 (0) 0 (0) 1 (1.0)
Number of individuals and percentage (%) are indicated.
Participants were classified, following Spanish Society of
Respiratory Pathology (SEPAR) guidelines (Ruiz-Manzano et al.,
2008) and also Centers for Disease Control and Prevention
(CDC) recommendations (Centers for Disease Control and
Prevention, 2000), in four groups depending on the TB status,
as is described in detail below. The method used for diagnosing
LTBI was TST (PPD RT23, Statens Serum Institute, Copenhagen,
Denmark) and QuantiFERON-TB Gold In Tube (QFN; QIAGEN,
Düsseldorf, Germany).
The following individuals were included as no LTBI: (a) indi-
viduals from LTBI screening studies, who tested QFN negative
and TST under 10 or 15mm (depending on the absence or
presence of BCG vaccination, respectively); and (b) individuals
who reported contact with a TB patient and with negative QFN,
whose TST was under 5mm. All patients included were HIV
negative.
As LTBI were included: (a) individuals who reported a con-
tact with a TB patient or from LTBI screening studies, who tested
QFN positive; (b) individuals who reported an intense contact
with a TB patient, with negative QFN and TST higher than 5mm
(if the subject is BCG vaccinated, the index case has to be smear-
positive; if it is smear-negative, TST has to be higher than 15mm);
(c) individuals from LTBI screening studies, who tested QFN neg-
ative and whose TST converted (by definition, from under 10mm
to above 10mm with a change of 6mm); and (d) individuals
from LTBI screening studies, who tested QFN negative and TST
positive (higher than 10mm in non BCG-vaccinated and recent
immigrants; and higher than 15mm in BCG-vaccinated).
Individuals with pulmonary or extrapulmonary active TB,
clinically, radiologically and/or microbiologically diagnosed
(World Health Organization, 2013) were included.
MYCOBACTERIUM TUBERCULOSIS ANTIGENS
A total of 60 M.tb recombinant latency-related antigens were
evaluated (Table 2): 6 DosR regulon-encoded antigens, 12
TB reactivation-associated antigens, 1 Rpf antigen, 1 starva-
tion antigen, 6 other stress response-associated TB antigens
and 34 IVE-TB antigens (two of them were EHR and three
were EHR/starvation). They were previously produced at the
Department of Infectious Diseases, Leiden University Medical
Center following the methododology previously described
(Franken et al., 2000). Briefly, antigens were selected from RNA
microarray studies after inducing hypoxic conditions in a M.tb
liquid culture. The selected genes were cloned in Escherchia coli
and antigens were overexpressed and purified by immobilized
metal chelate affinity chromatography. Some antigens were pre-
pared as two or three recombinant protein fragments owing to
their large sizes (C, middle [M], and N termini). For IVE-TB
genes, mice were infected with M.tb and RNA was isolated from
mouse lung tissue (Commandeur et al., 2013). After a RT-PCR,
highly or differentially expressed genes were selected and cloned
by Gateway technology (Invitrogen, Carlsbad, US) in E. coli and
antigens were obtained as explained before.
Apart from those M.tb recombinant antigens, we used 4
control antigens for which immunogenicity and specificity to
M.tb is well defined: the fusion protein ESAT-6 [Rv3875]/CFP-
10[Rv3874], Ag85A[Rv3804c], TB10.4[Rv0288], and PPD (PPD
RT 23, Serum Institute, Copenhagen, Denmark).
Antigens were reconstituted in sterile phosphate buffered
saline, to a concentration of 50μg/mL and stored at −20◦C.
The 60 latency-related antigens were randomly grouped into
10 batches of 6, and the individuals tested randomly selected.
Thus, the whole blood from each patient was stimulated with six
antigens, and the four control antigens as well.
WHOLE BLOOD ASSAY
400μL of whole blood were transferred to a 48 well culture
plate (Nunc, St. Louis, US) and control antigens were added
at a final concentration of 10μg/mL except for PPD, that was
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Table 2 | Description of the 4 control and 60M.tb recombinant
antigens tested, included DosR regulon-encoded (n = 6), TB
reactivation-associated (n = 12), Rpf (n = 1), starvation (n = 1), other
stress response-associated (n = 6), and IVE-TB antigens (n = 34)
(Function information source: http://www.ncbi.nlm.nih.gov/
nuccore).
Antigen name Function
CONTROL ANTIGENS (n = 4)
PPD Purified protein derivative
Rv0288 (TB10.4) Low molecular weight protein antigen
belongs to the ESAT-6 (esx) family
Rv3875/3874
(ESAT-6/CFP-10)
6-kDa early secretory antigenic
target/10 kDa culture filtrate (fusion protein)
Rv3804c (Ag85A) Secreted antigen. Fibronectin binding
protein acyltransferase activity
M.tb RECOMBINANT ANTIGENS (n = 60)
DosR
Rv0570c Probable ribonucleoside-diphosphate
reductase C-ter (aa 333-692)
Rv0570n Probable ribonucleoside-diphosphate
reductase N-ter (aa 1-354)
Rv1733 Probable conserved transmembrane protein
Rv2626 Conserved hypothetical protein
Rv2627 Conserved hypothetical protein
Rv2628 Hypothetical protein
Reactivation
Rv0140 Conserved hypothetical protein
Rv0251 Possible heat shock protein
Rv0384 Heat shock protein F84.1
Rv0753 Methylmalmonate semialdehyde
dehydrogenase
Rv1471 Thioredoxin reductase
Rv1874 Hypothetical protein
Rv1875 Conserved hypothetical protein
Rv2465* Phosphopentose isomerase
Rv2466 Conserved hypothetical protein
Rv2662 Hypothetical protein
Rv3223 ECF subfamily sigma subuint
Rv3862 Possible transcriptional regulatory protein
WHIB6
Rpf
Rv2389 Possible resuscitation promoting factor D
Starvation
Rv2660 Hypothetical protein
OtherM.tb stress induced
Rv0244 Probable Acyl-coA dehydrogenase
Rv0767 Conserved hypothetical protein
Rv1909 Ferric uptake regulation protein
Rv2745 Possible transcriptional regulatory protein
Rv2913 Possible D-amino acid amonohydrolase
Rv3406 Probable dioxygenase
IVE-TB
Rv0847 Probable LpqS, lipoprotein
(Continued)
Table 2 | Continued
Antigen name Function
Rv0967 Copper-sensitive operon repressor
Rv0990 Hypothetical protein
Rv0991 Conserved serine rich protein
Rv1170 N-acetyl-1-D-myo-inosityl-2-amino-2-deoxy-
alpha-D-glucopyranoside deacetylase
MshB
Rv1284* = Conserved hypothetical protein
Rv1363 Possible membrane protein
Rv1403 Putative methyltransferase
Rv1806 PE family protein PE20
Rv1955 Possible toxine HigB
Rv1956* = Possible antitoxin HigA
Rv1957 Hypothetical protein
Rv2034* = ArsR repressor protein
Rv2035 Conserved hypothetical protein
Rv2225 3-methyl-2-oxobutanoate
hydroxymethyltransferase (panB)
Rv2324* Probable transcriptional regulatory protein
(probably AsnC-family)
Rv2380c Peptide synthetase mbtE C-ter (aa
1120-1682)
Rv2380M Peptide synthetase mbtE middle part (aa
560-1140)
Rv2380N Peptide synthetase mbtE N-ter (aa 1-580)
Rv2435c Probable cyclase (adenylate or guanylate
cyclase) C-ter (aa 340-730)
Rv2435n Probable cyclase (adenylate or guanylate
cyclase) N-ter (aa 1-360)
Rv2558 Conserved protein
Rv2642 Possible transcriptional regulatory protein
Rv2643 Probable arsenic-transport integral
membrane protein ArsC
Rv2658 Possible prophage protein
Rv2737c Recombination protein recombinase A
(recA) C-ter (aa 400-790)
Rv2737n Recombination protein recombinase A
(recA) N-ter (aa 1-420)
Rv2838 Probable ribosome-binding factor A (P15B
protein)
Rv2982 Probable glycerol-3-phosphate
dehydrogenase (gpdA2)
Rv3353 Conserved hypothetical protein
Rv3420 Ribosomal-protein-alanine acetyltransferase
rimI
Rv3515* Fatty-acid-CoA synthase
Rv3536 Probable hidratase
Rv717 30S ribosomal protein S14 RpsN1
M.tb recombinant antigens with Rv designation in bold induced a relevant IFN-γ
response in this study.
*also EHR.
=also starvation
added at 1μg/mL. M.tb recombinant antigens were tested at a
final concentration of 10μg/mL. A negative (RPMI medium;
PAA, Pasching, Austria) and a positive control of immunity
(phytohemagglutinn, Invitrogen, Carlsbad, US) were included.
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This procedure was performed in two different plates: one plate
was incubated in a 5% CO2 incubator a 37◦C overnight (18 h,
short-term stimulation) and the other for 7 days (long-term
stimulation). In the long-term incubation plate, blood was pre-
viously diluted 1:5 with RPMI 1640 medium supplemented with
L-glutamine, penicillin and streptomycin (Weir et al., 2003). After
incubation time, supernatants were then collected and stored
at −80◦C until tested.
DETERMINATION OF IFN- γ BY ELISA
The measurement of the amount of IFN-γ released follow-
ing the antigenic stimulation was evaluated by the commer-
cial ELISA included in the QFN kit and data are presented as
pg/mL after subtraction of the negative control. We considered
a valid result when the value of the negative control was under
50 pg/ml. The cut-off value for high level of IFN-γ response
was arbitrarily set at 20 pg/ml, taking as reference the QFN
cut-off.
STATISTICAL ANALYSIS
The production level of IFN-γ was compared between the groups
included in the study. Median and range of the cytokine produc-
tion was calculated andMannWithney test was used for pair-wise
comparisons and Kruskall Wallis test was used for multiple com-
parisons. A P-value <0.05 was considered significant. Data were
analyzed using SPSS statistical software (IBM SPSS Statistics 20;
IBM Corporation, NY, USA). Graphical representation is based
on GraphPad Prism version 4 (GraphPad Software, Inc., San
Diego, CA).
RESULTS
From the 578 participants, 60 were not tested for the determina-
tion of IFN-γ because of insufficient samples, eight subjects did
not fulfill the inclusion criteria and five subjects were excluded
from the study because the amount of IFN-γ in the negative con-
trol was too high. In the patients PHA induced high responses,
which ratifies the validity of our methodology.
IMMUNOGENICITY OF CONTROL TB ANTIGENS
We included four control antigens in our study. Significant dif-
ferences in the IFN-γ responses elicited by all of them could
be observed between the three study groups after short-term
and after long-term stimulation (Tables 3, 4). The antigens that
elicited a higher response were PPD and the fusion protein
ESAT-6/CFP-10, followed by TB10.4 and Ag85A.
IMMUNOGENICITY OF DosR REGULON-ENCODED ANTIGENS
We evaluated six different DosR regulon-encoded antigens
(Figure 1). Two of them were the C-ter and N-ter domain of
a latency antigen (Table 2). There were three antigens which
presented a differentiated response depending on the TB sta-
tus group: Rv1733, Rv2627, and Rv0570c (Tables 3, 4). While
Rv1733 discriminated between groups when the stimulation was
either short-term or long-term, the discrimination of Rv2627
only was significant after short-term stimulation, and Rv0570c
was only after long-term stimulation (although with a low IFN-γ
response). The best discriminatory response was elicited when
whole blood was stimulated overnight with Rv1733 (p = 0.001),
where the infected individuals response was clearly much higher
Table 3 | Median levels of IFN-γ (pg/ml), minimum and maximum values (in brackets) elicited in no TB infected individuals, subjects with LTBI
and active TB patients by the antigens, when tested after short-term stimulation.
Antigen No TB infection TB infection Active TB p-value
n Median n Median n Median
CONTROL
PHA 95 907.0 (26.3, 5396.5) 294 807.5 (19.5, 12132.0) 98 139.3 (0.0, 2943.5) 0.000
PPD 90 25.5 (0.0, 502.5) 275 57.3 (0.0, 1299.0) 95 19.5 (0.0, 1198.0) 0.000
TB10.4 94 3.5 (0.0, 125.5) 288 9.3 (0.0, 581.5) 91 3.0 (0.0, 355.7) 0.003
ESAT6/CFP10 94 6.5 (0.0, 591.0) 280 20.3 (0.0, 2758.5) 91 5.5 (0.0, 752.0) 0.005
Ag85A 88 0.0 (0.0, 69.5) 262 1.0 (0.0, 145.0) 78 0.5 (0.0, 311.0) 0.011
DosR
Rv2627 16 0.8 (0.0, 5.0) 54 1.0 (0.0, 34.5) 6 0.0 (0.0. 0.5) 0.044
Rv1733 4 32.8 (12.0, 66.5) 20 69.8 (0.5, 733.0) 9 3.0 (0.0, 32.5) 0.001
REACTIVATION
Rv1471 4 3.8 (0.0, 9.0) 19 1.5 (0.0, 19.0) 8 0.0 (0.0, 0.5) 0.010
Rv1874 4 2.3 (0.0, 3.0) 19 1.0 (0.0, 9.5) 7 0.0 (0.0, 0.5) 0.009
Rv3862 7 2.0 (0.0, 14.0) 21 4.5 (0.0, 32.5) 9 0.0 (3.0, 4.0) 0.019
IVE-TB
Rv0967 8 1.8 (0.0, 13.0) 19 3.0 (0.0, 253.0) 10 0.0 (0.0, 1.5) 0.017
Rv1806 7 5.0 (0.0, 35.5) 15 7.5 (0.0, 56.5) 7 1.0 (0.0, 3.5) 0.023
Rv1957 4 2.8 (0.0, 5.5) 19 0.5 (0.0, 18.5) 8 0.0 (0.0, 0.5) 0.020
N indicates the number of subjects in each group. Data were analyzed by Kruskal Wallis test for the comparison of no TB infection, TB infection, and active TB
groups of patients. Only significant differences (p < 0.05) were included.
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Table 4 | Median levels of IFN-γ (pg/ml), minimum and maximum values (in brackets) elicited in no TB infected individuals, subjects with LTBI
and active TB patients by the antigens, when tested after long-term stimulation.
Antigen No TB infection TB Infection Active TB p-value
n Median n Median n Median
CONTROL
PHA 94 1136.0 (189.8, 6443.0) 293 1013.9 (296.5, 12135.5) 102 854.3 (0.0, 4026.3) 0.000
PPD 89 13.5 (0.0, 925.5) 275 59.5 (0.0, 2246.0) 99 60.0 (0.0, 1681.2) 0.000
TB10.4 94 1.6 (0.0, 115.0) 288 3.2 (0.0, 1154.0) 100 1.5 (0.0, 675.0) 0.004
ESAT6/CFP10 93 86.0 (0.0, 2818.5) 280 163.5 (0.0, 6440.0) 100 29.7 (0.0, 3966.0) 0.000
DosR
Rv0570c 8 0.0 (0.0, 4.5) 19 0.0 (0.0, 5.0) 5 1.5 (0.5, 5.5) 0.012
Rv1733 4 345.3 (178.5, 2766.5) 20 356.5 (3.5, 2150.0) 10 7.3 (1.0, 394.5) 0.010
REACTIVATION
Rv1471 3 2.0 (1.5, 38.5) 15 1.0 (0.0, 25.5) 8 10 (0.0, 1.5) 0.028
Rpf, OTHER STRESS-INDUCED
Rv0244 8 17.8 (5.0, 50.0) 24 7.3 (0.0, 63.5) 8 0.3 (0.0, 4.5) 0.005
Rv2389 7 148.5 (12.0, 257.0) 16 135.8 (1.5, 610.5) 5 22.5 (5.0, 59.5) 0.046
IVE-TB
Rv0847 7 6.5 (2.5, 182.5) 21 3.5 (0.0, 298.5) 9 1.0 (0.0, 111.0) 0.011
Rv2558 4 1.0 (0.0, 2.5) 17 0.0 (0.0, 2.0) 9 0.5 (0.0, 6.5) 0.038
Rv2642 3 23.5 (16.5, 315.0) 15 33.5 (1.5, 191.0) 8 1.0 (0.0, 3.5) 0.002
N indicates the number of subjects in each group. Data were analyzed by Kruskal Wallis test for the comparison of no TB infection, TB infection, and active TB
groups of patients. Only significant differences (p < 0.05) were included.
than in TB patients and higher than the response produced by
non-infected individuals. When incubated for 7 days, Rv1733 also
induced a high amount of IFN-γ released in infected individu-
als, being the response much higher than in TB patients. Rv1733
turned out to be a strong immunoresponse inducer, a promis-
ing LTBI biomarker and a promising antigen in discriminating
between LTBI individuals, active TB patients and non-infected
subjects. The Rv1733, considering the 20 pg/ml as a cut-off,
accurately predicted 85% (17/20) of LTBI patients in short-term
stimulation; and 95% (19/20) in long-term stimulation.
IMMUNOGENICITY OF TB REACTIVATION-ASSOCIATED ANTIGENS
A total of 12 TB reactivation-associated antigens were evaluated
in the study (Figure 2). In general, recognition of these anti-
gens was poor in subjects with LTBI and TB patients. However,
there were several antigens which showed different IFN-γ pro-
duction depending on the group of individuals (Tables 3, 4).
While Rv1471, Rv1874, Rv1875, Rv2662, and Rv3862 induced
differentiate response in infected individuals in short-term stim-
ulation; Rv1471, Rv2622, and Rv3862 induced differentiate and
high response in infected individuals in long-term stimulation.
IMMUNOGENICITY OF Rpf, STARVATION AND OTHER STRESS
RESPONSE-ASSOCIATED ANTIGENS
We tested 1 Rpf, 1 starvation, and 6 other stress response-
associated antigens (Figure 3). The response to some of those
antigens did present statistical differences when compared among
groups (Tables 3, 4). Rv2389, and Rv0244 in short and long-
term estimulation, and Rv1909 in long-term stimulation induce
high response in infected individuals. However, in some of them
relevant production of IFN-γ after the stimulation in non-
infected individuals was observed. Rv2389 accurately predicted
81% (13/16) of LTBI patients in long-term stimulation.
IMMUNOGENICITY OF IVE-TB ANTIGENS
We evaluated the immunogenicity of 34 IVE-TB antigens
(Figure 4). The LTBI individuals were the group that most
recognized IVE-TB antigens, although the response level was
not very high (Tables 3, 4). In addition to the antigens that
induce a significant IFN-γ response (Rv0967, Rv1806, and
Rv1957 after short-term stimulation; and Rv0847, Rv2558, and
Rv2642 after long-term stimulation), several antigens obtained
IFN-γ response in infected individuals: Rv0847, Rv0990, Rv0991,
Rv1363, Rv1955, Rv2034, Rv2035, Rv2435n, Rv2642, Rv2643,
Rv2658, Rv3420, and Rv3536 after short-term stimulation; and
Rv1363, Rv1806, Rv2435n, Rv2643, Rv25658, and Rv3536 after
long-term stimulation. However, in some of them the amount of
IFN-γ was not very high, and the regions of response overlapped
with the response obtained in non-infected individuals.
COMPARISON BETWEEN QFN-POSITIVE AND QFN-NEGATIVE LTBI
INDIVIDUALS
Given that the lack of specificity of the TST, we evaluated if
the response of LTBI individuals to the 60 novel latency-related
mycobacterial antigens varied according to the result of their
QFN. There were four antigens to which the response was sta-
tistically different depending on the QFN result (Table 5) when
used in short-term stimulation. Latently infected individuals
responded to Rv2389 (p = 0.029) and Rv2435n (p = 0.050) in
higher amounts when the individual presented a positive QFN,
thus indicating to be promising LTBI biomarkers. However, the
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FIGURE 1 | DosR regulon-encoded antigen stimulated IFN-γ response
(pg/ml) after short (A) or long-term (B) incubation of whole blood from
individuals without LTBI (black dots), with LTBI (gray dots), and active
TB patients (empty dots). The horizontal line represents the median.
response to Rv2435n overlapped between the two groups. The
other two antigens, Rv2660 and Rv2380M, induced a signifi-
cant response in individuals with a negative QFN (p = 0.046 and
p = 0.030, respectively), indicating to be possible candidates for
remote infection. The response to Rv2380M barely overlapped
in the two groups, whereas the response to Rv2660 clearly over-
lapped. Some of these antigens could be good candidates to be
used in combination with the QFN.
EFFECT OF BCG VACCINATION IN THE RESPONSE TO STUDIED
ANTIGENS IN INDIVIDUALS WITH ANDWITHOUT LTBI
Among non-infected individuals, there were five antigens in
which the response was different according to the vaccina-
tion status. Specifically, Rv717, Rv0570n, Rv2658, and Rv2643
induced a significant response in BCG vaccinated individuals
(p = 0.043, p = 0.009, p = 0.041, p = 0.041, respectively). In
contrast, it was the non-BCG vaccinated individuals who most
responded to Rv2627 (p = 0.019). Interestingly, while the higher
response to antigens in BCG vaccinated individuals was pro-
duced after short-term stimulation, the higher response elicited
by non-vaccinated individuals was only produced after long-term
stimulation.
Regarding the LTBI subjects, BCG vaccinated individuals
elicited a significant response to the following antigens: Rv2035,
Rv1471, Rv1957, and Rv2435n (p = 0.016, p = 0.020, p = 0.020,
p = 0.015, respectively) when compared to non-BCG subjects. In
all four antigens the significance was after overnight stimulation.
DISCUSSION
In this study we evaluated whether latency antigens induced
a response which varied according to the group of individu-
als. Each category of antigens, that is, DosR regulon-encoded,
TB reactivation-associated, Rpf, starvation, IVE-TB antigens and
other stress response-associated TB antigens, contained at least
one antigen whose statistical analysis was significative.
Regarding the control antigens we studied, in general, the
response they induced was higher after 7 days of incubation. PPD
and ESAT-6/CFP-10 were the antigens which induced a highest
response, followed by the TB10.4 and finally Ag85A, which is in
concordance with what Kassa et al. (2012) found. According to
our finding, Chegou et al. (2012) observed that the majority of
response toM.tb infection is largely driven by ESAT6/CFP-10, not
by the other antigens that they used as controls (TB7.7, Ag85A/B,
and HSP65), where the recognition was poor. Generally speak-
ing, it was observed that infected individuals provided higher
responses than those with the disease. In a study performed by
Sutherland et al. (2013) it was found, instead, that PPD and ESAT-
6/CFP-10 generated dominant responses but very few differences
between active TB and LTBI subjects. In the present study, some
antigens induced a lower response in active TB patients when
compared with non-TB infected subjects. This fact could be
explained by the criteria selection followed for including indi-
viduals in the non-infected group. In our study, patients from
LTBI screening with negative QFN, but TST results under 10mm
(non BCG-vaccinated) or 15mm (BCG-vaccinated) were consid-
ered non-infected, but in some cases some cross-reactivity with
the antigens used as a control (including ESAT-6/CFP-10) and
the latency antigens could not be rejected. Indeed, in general, in
the group of non-infected individuals the IFN-γ responses against
ESAT-6/CFP-10 are lower in patients with TST under 5mm, than
in patients with TST over 5mm (data not shown). On the other
hand, results in the literature regarding IFN-γ responses to the
these antigens in active TB patients are inconsistent. Possible dif-
ferences may reside in variations in host genetic makeup, M.tb
strains, studymethodologies or the extent of TB progression, with
diminished IFN-γ production during advanced disease (Weir
et al., 2003; Jabado and Gros, 2005; Tsenova et al., 2007; Winek
et al., 2008; Day et al., 2011).
Among allM.tb recombinant antigens we studied, there is one
which stands up significantly: Rv1733, which is a probable con-
served transmembrane protein and is part of the DosR regulon.
As it can be observed in Figure 1, this antigen induces a differenti-
ated response between non-infected subjects, infected individuals
and TB patients. Specifically, infected individuals are the ones
that generate a highest response, followed by the non-infected,
and by the patients with the active disease at the end. Rv1733
immunogenity has been previously analyzed, and a genomic
study from Zvi et al. (2008) describes it as an immunodomi-
nant T cell antigen. Moreover, many authors agree that there is
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FIGURE 2 | TB reactivation-associated antigen stimulated IFN-γ response (pg/ml) after short (A) or long-term (B) incubation of whole blood from
individuals without LTBI (black dots), with LTBI (gray dots), and active TB patients (empty dots). The horizontal line represents the median.
significantly higher T cell response in LTBI as compared to TB
patients (Vordemeier et al., 1991; Leyten et al., 2006; Black et al.,
2009; Schuck et al., 2009; Commandeur et al., 2011; Sutherland
et al., 2013), and Rv1733 is one of the DosR antigens that induces
a highest response. Interestingly enough, this response pattern
against Rv1733 is produced after the stimulation during 24 h,
which makes it very appealing to be used for diagnostic purposes.
In contrast with our finding, Riaño et al. (2012) observed that
LTBI and TB patients did not react to Rv1733. In another study
with TB patients, a high response to Rv1733 was also obtained
(Kassa et al., 2012).
Even though Rv1733 turned out to be a very immunogenic
antigen, Rv2389, which belongs to the Rpf family, induced a
high response in most of the individuals as well. Kassa et al.
(2012) described that the Rv2389 was able to induce a high IFN-
γ response in active TB patients. In fact, the immunoresponse to
Rpf may play a protective role against bacilli reactivation (Riaño
et al., 2012). Rv2389 was able to differentiate between non-
infected individuals, individuals with LTBI and active TB patients
when incubated with whole blood for 7 days, even though some
overlapping is present. As observed by Chegou et al. (2012), active
TB patients response was much lower than in non-TB individ-
uals. Commandeur et al. (2011), demonstrated Rv2389 specific
T cell response in long-term M.tb nonprogressors to active TB
patients. Riaño et al. (2012), observed higher levels of IFN-γ
in the supernatant of stimulated cells from LTBI compared to
active TB patients. Huang et al. (2013) demonstrated that LTBI
infected through household contacts possessed higher IFN-γ pro-
duction to Rv2389c than did the community exposed individuals.
In addition, QFN-positive individuals responded in a higher
level to Rv2389 when compared to QFN-negative individuals.
The Rv2389 ability of discriminate between these two groups of
patients have been confirmed by receiver operating characteris-
tics curve (ROC) analysis (area under curve = 0.877). Altogether,
these findings indicate that Rv2389 would be a good biomarker
of LTBI.
Concerning the recently identified IVE-TB antigens, the
only research group that has studied their immunogenicity
in vitro found that some of them induced high levels of IFN-γ
(Commandeur et al., 2013). In our study, some antigens showed
a certain difference when comparing the three groups of indi-
viduals. While the median value was quite low in all groups,
a great number of antigens such as Rv0967, Rv1363, Rv1957,
Rv2034, Rv3420, or Rv2642 among others were able to induce
outstanding IFN-γ responses in some individuals. In concor-
dance with the study performed by Commandeur and coworkers,
it was the active TB patients the group who showed a lowest
response. They observed that the individuals who generated a
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FIGURE 3 | Rpf, starvation and other stress response-associated
antigen stimulated IFN-γ response (pg/ml) after short (A) or
long-term (B) incubation of whole blood from individuals
without LTBI (black dots), with LTBI (gray dots), and active
TB patients (empty dots). The horizontal line represents the
median.
highest response were those that did it with ESAT-6/CFP-10 as
well. They also observed that controls not exposed to M.tb and
individuals with positive TST and negative response to ESAT-
6/CFP-10 did not respond to IVE-TB antigens, which shows
that there is a specificity linked to M.tb exposure. In our study,
although some non-TB infected individuals produced IFN-γ after
being stimulated with IVE-TB antigens, individuals with LTBI
also responded as well. BCG vaccine was ruled out as the response
trigger in subjects without LTBI, as T cells from non-BCG vacci-
nated individuals generated a response as well. However, due the
difficulty of totally rule out the infection in the no LTBI individu-
als, we cannot reject that, alternatively, those responder non-BCG
vaccinated individuals were really M.tb infected; and that the
responder BCG-vaccinated individuals were, in fact, responding
to the shared BCG antigens.
Interestingly, the response to Rv2380M and Rv2660 was higher
in individuals with a negative QFN than subjects with a positive
QFN, indicating that both antigens could be possible biomark-
ers for remote infection. In the opposite way, Rv2435n induced
a higher response in subjects with positive QFN. It may be,
therefore, a possible biomarker for recent infection.
Activated lymphocytes and effector T cells that produce IFN-γ
from M.tb antigens sensitized individuals, persist for a limited
time in the circulation once the antigen is cleared (Pathan et al.,
2001). It is thought that central memory T cells, but not effec-
tor ones, may take several days (rather than hours) to produce
effector cytokines (Kaech et al., 2002; Dheda et al., 2007). This
is because, the commercial IGRAs are thought to reflect more
recent, rather than remote infections. Therefore, contrary to the
findings of the TST, in cases of remote infection, the IFN-γ level
did not increase during the short period of exposure to the anti-
gen in the ex vivo IFN-γ assay at baseline. For these reasons we
chose to stimulate short and long term the blood samples with
the different latency-related antigens. Interestingly, the higher
IFN-γ responses have been obtained after long-term stimula-
tion instead of short-term stimulation: Rv1733, Rv3862, Rv2662,
Rv0244, Rv2389, Rv1909, Rv2435n, Rv0847, Rv0967, Rv1806, and
Rv2642.
As far as we know, only Goletti et al. (2010) assessed the
comparison between individuals recently and remotely infected
to five latency mycobacterial antigens. They found that Rv2628
was able to differentiate recent from remote infection, being the
individuals with remote infection the group that showed signifi-
cantly higher IFN-γ whole blood responses. In a very preliminary
results, using well TB status characterized individuals, we have
observed that responses to some antigens (Rv2380M, Rv0967,
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FIGURE 4 | IVE-TB antigen stimulated IFN-γ response (pg/ml) after short (A,B) or long-term (C,D) incubation of whole blood from individuals without
LTBI (black dots), with LTBI (gray dots), and active TB patients (empty dots). The horizontal line represents the median.
Table 5 | Median levels of IFN-γ (pg/ml), minimum, and maximum
values (in brackets) elicited in latently infected individuals depending
on the QFN result.
Positive QFN Negative QFN
Antigen n Median n Median p-value
Rv2389 13 9.0 (0.0, 95.5) 5 0.5 (0.0, 2.5) 0.029
Rv2660 15 0.0 (0.0, 18.5) 6 1.0 (0.0, 3.5) 0.046
Rv2380M 13 0.0 (0.0, 1.0) 6 3.3 (1.0, 4.5) 0.003
Rv2435n 10 10.5 (0.0, 92.5) 7 1.0 (0.0, 39.0) 0.05
N indicates the number of subjects in each group. Data were analyzed by Mann
Whitney test for the comparison of patients with positive QFN and negative
QFN. Only significant differences (p < 0.05) were included.
Rv2435n, and Rv2913) could differentiate between recent and
remote infection (data not shown).
The fact of not obtaining response to an antigen that other
studies identify as immunogenic, can be due to different host
immune responses, M.tb strains and variations in the method-
ology used (Ottenhoff et al., 1998; Caws et al., 2008; Homolka
et al., 2010), and also some factors such as ethnicity (host genet-
ics), nutritional status, and microbial environment (Sutherland
et al., 2013). The discordance in results between studies could
be also attributed to the lack of gold standard for defining
LTBI, and the consequent heterogenicity in the study population
included in the different studies. The difficulty of establishing a
group of LTBI is demonstrated by the criteria followed by the
different authors: Leyten et al. (2006) included both patients from
contact-tracing studies and also from screening studies; Chegou
et al. (2012) included contact-tracing studies individuals, where
neither TST nor QFN results were available; Commandeur et al.
(2013) included TST positive patients, with exposure to M.tb
and or with history of traveling to high TB incidence coun-
tries; and Sutherland et al. (2013) included household contacts
of TB patients or by random community selection or from HIV
care clinics with TST higher than 10mm in HIV negative, and
higher than 5 in HIV positive (independently of the BCG sta-
tus). According to a recent study (Sutherland et al., 2013), which
includes individuals from different sub-Saharan African coun-
tries, despite possible differences in the criteria of study subjects,
there were variations between sites in regards to antigen reactivity,
suggesting that need to be considered.
In order to ensure the validity of the promising antigens, we
decided to study if some antigens induced a different response
depending on whether the individual had been vaccinated with
BCG or not. Among the antigens that distinguished between
non-infected individuals, infected individuals and patients with
TB disease, three of them were also identified when we analyze
the effect of the BCG: Rv2627, Rv1471, and Rv1957. In order
to measure the magnitude of the BCG influence, the response
of non-vaccinated individuals was assessed. Being p > 0.05 and
the charts showing an overlapping of the response between the
three groups it seems that BCG has a considerable influence in
the results (data not shown).
The effect of the BCG on the immune response against latency
M.tb antigens has been studied by other authors. Lin et al.
(2007) found that, although the homology between the DosR
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regulon from the BCG strain and fromM.tb was very high, BCG-
vaccinated individuals did not present immune response against
DosR. Instead, individuals exposed toM.tb did respond to DosR.
Thus, it seems that the response to antigens linked to the con-
trol of LTBI is only generated when there is an exposure to
M.tb, and it does not depend on whether the individual has been
immunized by the BCG, probably because BCG fails to estab-
lish long-lived latent infections, and therefore it may not express
(or under express) these antigens in vivo following vaccination
(Honaker et al., 2008). However, this issue warrants further
investigation.
The current study presents certain limitations which are worth
mentioning. In the first place, it is worth highlighting the dif-
ficulty found in the classification of the individuals according
to their TB status, specially among BCG-vaccinated individuals,
since there is no gold standard assay for LTBI diagnosis. We there-
fore cannot rule out in some cases a misclassification. Secondly,
it seems that some of the studied antigens could present certain
lack of specificity; they could be shared in BCG strain and also
in other mycobacteria (Lin et al., 2009), since some non-infected
and non BCG-vaccinated individuals responded. Anyway, it is
not clear whether the cross-reactivity to latency antigens in M.tb
naive people contributes to the natural protection developed in
90% of the individuals who are infected but do not progress to
active TB (Fine, 1995; Brandt et al., 2002). Thirdly, the sample
size we could include was certainly limited for some antigens,
including some antigens found as promising. Another limitation
of our work lies in the fact that we only evaluated the immunore-
sponse in terms of IFN-γ production by T cells. Combination of
other cytokines with IFN-γ can strengthen the diagnostic poten-
tial of M.tb antigen (Goldsack and Kirman, 2007). However,
despite these limitations, this work obtained strong conclusions
identifying potential antigens as candidates for further validation
studies.
In conclusion, after screening the potential antigenicity in
subjects across the spectrum of TB, we could identify promis-
ing antigens in all groups of antigens studied. Rv1733, which is
encoded in DosR regulon, turned out to be very immunogenic
and able to discriminate between the three defined TB status, thus
considered a candidate biomarker. Rv2389 and Rv2435n, belong-
ing to Rpf family and IVE-TB group of antigens, respectively, also
stood out as LTBI biomarkers. Further work needs to be done
in order to support our hypothesis and to have a pattern of host
responses available so that by testing the response to a set ofM.tb
antigens we can define the TB status and make a clinical decision.
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